Chatchanan Doungkamchan

Dr. Chatchanan Doungkamchan

Chulalongkorn University, Bangkok, Krung Thep Maha Nakhon, Thailand
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
LRLucksica Ruangapirom
Lucksica Ruangapirom
NSNannapat Sutivijit
Nannapat Sutivijit
CTChinachote Teerapakpinyo
Chinachote Teerapakpinyo
AMApiwat Mutirangura
Apiwat Mutirangura
CDChatchanan Doungkamchan
Chatchanan Doungkamchan
Personalized neoantigen-based cancer vaccines have been shown to be safe and immunogenic in cancer patients; however, the manufacturing process can be costly and bring about delays in treatment. Using off-the-shelf cancer vaccines targeting shared neoantigens may circumvent these problems. Unique mutational signatures and similar phenotypes found among BRCA1-mutated breast cancer make it an ideal candidate for discovering shared neoantigens within the group. We obtained genome sequencing data of breast cancer samples with or without somatic BRCA1 mutations (BRCA1-positive and BRCA1-negative, respectively) from the three public cancer databases; The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and Catalogue of Somatic Mutations in Cancer (COSMIC); and from three studies with whole genome/exome sequencing data of samples with germline BRCA1 mutations. Data were analyzed separately within the same database/cohort. We found PIK3CA H1047R, E545K, E542K, and N345K recurrently in BRCA1-negative groups across all databases, whereas recurrent somatic mutations in BRCA1-positive groups were discordant among databases. For germline BRCA1-mutated breast cancer, TP53 R175H was unanimously the most frequent mutation among the three germline cohorts. Our study provides lists of potential shared neoantigens among BRCA1-related breast cancer, which may be used in developing off-the-shelf neoantigen-based vaccines.

25 February 2022 in Stem Cell Research
Verified
Journal Article
Open access
KTKien T.D. Tran
Kien T.D. Tran
YSYi Sheng
Yi Sheng
CDChatchanan Doungkamchan
Chatchanan Doungkamchan
CCCarlo A. Castro
Carlo A. Castro
KOKyle E. Orwig
Kyle E. Orwig
Infertility is a common disease that impacts 15% of reproductive age couples worldwide, and genetic causes are implicated in about half of those cases. Non-obstructive azoospermia is a severe form of male infertility that features spermatogenic failure resulting in no sperm in the ejaculate and severely reduces the chance to have biological children. We created a Tex11_1260Ins(TT) (1260GATA → TTGGTA) mutant mouse that models the Tex11_1258(TT) mutation identified from a patient with nonobstructive azoospermia. The Tex11_1260Ins(TT) iPSC cells displayed characteristics of pluripotent-like morphology, expressed pluripotent protein markers, show normal karyotype, and can to differentiate into tissues of the three germ layers.

30 March 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
TBThanyaporn Buakaew
Thanyaporn Buakaew
RTRattapoom Thaiwong
Rattapoom Thaiwong
TIThananya Inthanachai
Thananya Inthanachai
TPTanapat Palaga
Tanapat Palaga
DWDrew Weissman
Drew Weissman
STSupannikar Tawinwung
Supannikar Tawinwung
Autologous chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in hematologic malignancies but remain limited by complex manufacturing processes. Allogeneic, off-the-shelf CAR T cells derived from healthy donors represent a promising alternative; however, safe implementation requires elimination of endogenous T-cell receptor (TCR) expression and flexible CAR expression strategies. This study aimed to develop an optimized manufacturing workflow for allogeneic CAR T cells by combining CRISPR/Cas9-mediated TCR knockout with mRNA-based CAR expression, and to evaluate cryopreservation strategies enabling on-demand CAR T-cell generation. Healthy donor T cells were edited at the TRAC locus using CRISPR/Cas9 to generate TCR-deficient T cells. These cells were cryopreserved and subsequently transfected with mRNA encoding CD117, BCMA, or CD19 CARs. CAR expression, cell viability, immunophenotype, cytokine secretion, and antigen-specific cytotoxicity were assessed under different cryopreservation-transfection conditions. TCR knockout T cells exhibited efficient TCR disruption with reduced alloreactive proliferation. CD117 mRNA CAR T cells derived from TCR-deficient T cells demonstrated CAR expression kinetics, immunophenotypic profiles, and antigen-specific cytotoxicity comparable to wild-type CAR T cells. Evaluation of two cryopreservation strategies revealed that cryopreservation prior to mRNA electroporation preserved cell viability, phenotype, and cytotoxic function, whereas cryopreservation after mRNA transfection was associated with reduced functional activity. The optimized protocol was successfully extended to CD19- and BCMA-targeting CAR mRNAs. Collectively, these findings establish a modular platform for producing allogeneic CAR T cells using mRNA technology, offering a practical approach for rapid, on-demand CAR T-cell therapy.

18 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
GAGeorgia Rae J Atkins
Georgia Rae J Atkins
RHRachel L. Hvasta-Gloria
Rachel L. Hvasta-Gloria
CDChatchanan Doungkamchan
Chatchanan Doungkamchan
CPChristopher R. Pombar
Christopher R. Pombar
JHJimmaline J. Hardy
Jimmaline J. Hardy
KOKyle E. Orwig
Kyle E. Orwig
Non-obstructive azoospermia (NOA) is the absence of sperm in the ejaculate due to spermatogenic failure. Fifty percent of NOA cases are unexplained but may arise from unidentified genetic mutations. Variants in TEX11 have been identified in men with NOA; and Tex11 knockout in mice causes NOA. Here we attempt to validate three TEX11 variants discovered in NOA patients by knocking them into the orthologous region of the mouse genome using CRISPR/Cas9 gene editing. Compared to wild type (144.2 ± 9.87 mg; 1.7 ± 0.5 million sperm/cauda epididymis 4.8 ± 1.3 pups/breeding), Tex11D mice (frameshift mutation) had reduced testis weight (28.33 ± 1.16 mg); no sperm in the epididymis; and were infertile with a maturation arrest testicular phenotype. We did not observe any spermatogenesis or fertility defects Tex11A mice (missense mutation). Tex11L mice had reduced testis weight (87.5 ± 14.79 mg) and epididymal sperm counts (0.33±0.13 million/cauda epididymis) but an incompletely penetrant infertility phenotype (5.4 ± 1.13 pups/breeding) with one third of mice being infertile. Infertile Tex11L mice also had a distinct epididymal phenotype with reduced sperm density in the caput and no sperm in the cauda, which was filled with amorphous material.